Anti-Inflammatory Effect of Myristicin on RAW 264.7 Macrophages Stimulated with Polyinosinic-Polycytidylic Acid

Ji Young Lee and Wansu Park *

College of Oriental Medicine, Department of Pathology, Kyungwon University, Seongnam 461-701, Korea; E-Mail: hangl98@naver.com

* Author to whom correspondence should be addressed; E-Mail: pws98@kyungwon.ac.kr; Tel.: +82-31-750-8821; Fax: +82-31-750-8821.

Received: 15 July 2011; in revised form: 8 August 2011 / Accepted: 18 August 2011 / Published: 22 August 2011

Abstract: Myristicin (1-allyl-5-methoxy-3,4-methylenedioxybenzene) is an active aromatic compound found in nutmeg (the seed of Myristica fragrans), carrot, basil, cinnamon, and parsley. Myristicin has been known to have anti-cholinergic, antibacterial, and hepatoprotective effects, however, the effects of myristicin on virus-stimulated macrophages are not fully reported. In this study, the anti-inflammatory effect of myristicin on double-stranded RNA (dsRNA)-stimulated macrophages was examined. Myristicin did not reduce the cell viability of RAW 264.7 mouse macrophages at concentrations of up to 50 µM. Myristicin significantly inhibited the production of calcium, nitric oxide (NO), interleukin (IL)-6, IL-10, interferon inducible protein-10, monocyte chemotactic protein (MCP)-1, MCP-3, granulocyte-macrophage colony-stimulating factor, macrophage inflammatory protein (MIP)-1α, MIP-1β, and leukemia inhibitory factor in dsRNA [polyinosinic-polycytidylic acid]-induced RAW 264.7 cells (P < 0.05). In conclusion, myristicin has anti-inflammatory properties related with its inhibition of NO, cytokines, chemokines, and growth factors in dsRNA-stimulated macrophages via the calcium pathway.

Keywords: myristicin; dsRNA; inflammation; macrophages; cytokine
1. Introduction

Myristicin (1-allyl-3,4-methylenedioxy-5-methoxybenzene; CAS No. 607-91-0, Figure 1), or methoxysafrole, is a natural aromatic alkenylbenzene constituent found in the nutmeg, the dried ripe seed of *Myristica fragrans* [1,2].

![Figure 1. Structural formula of the alkenylbenzene myristicin.](image)

Myristicin is also found in basil, anise, cinnamon, clove, fennel, parsley, and star anise [3,4]. It is used as a fragrance in the cosmetic industry and as a flavouring agent in food [5]. In traditional medicine, myristicin has been used to treat cholera, stomach cramps, nausea, diarrhea, and anxiety [2]. Recently, it was reported that myristicin exerts antibacterial activity against Gram-positive and Gram-negative organisms [6], but the anti-inflammatory properties of myristicin on virus-infected macrophages are not yet fully reported.

Macrophages and their circulating monocyte form are potent defenders of physiological integrity by their mediation of crucial physiological and protective functions such as innate immunity and inflammatory reactions, foreign antigen presentation, and scavenging dead cells [7]. Nitric oxide (NO) production endows macrophages with cytotoxic activity against bacteria, viruses, fungi, protozoa, and tumor cells. However, excessive production of NO could be related with the development of septic shock, neuropathological diseases, rheumatoid arthritis, and other autoimmune disorders [8].

Cytokines, which are soluble proteins that are secreted by cells of the immune system, can alter properties of different cell types and provide essential communication signals for motile cells of the immune system [9], but excessive and uncontrolled production of these inflammatory cytokines may lead to serious systemic complications such as microcirculatory dysfunction, tissue damage, and septic shock, which can exact a high mortality [10].

The double-stranded RNA (dsRNA), which accumulates at various stages of viral replication, stimulates macrophages. Polyinosinic-polycytidylic acid (PIC) is considered as the synthetic analog of dsRNA. Like other pathogenic endotoxin, dsRNA-activated macrophages provokingly produce many kinds of inflammatory mediators, including NO, cytokines, chemokines, and growth factors, resulting in acute or chronic inflammation [11-13].

We have investigated the inhibitory effects of myristicin on PIC-induced inflammation using RAW 264.7 mouse macrophages and THP-1 human monocytes. In addition to the inhibitory effect on NO production in PIC-induced THP-1, our data demonstrate that myristicin inhibits the excessive production of NO, interleukin (IL)-6, IL-10, interferon inducible protein-10 (IP-10), monocyte chemotactic protein (MCP)-1, MCP-3, granulocyte-macrophage colony-stimulating factor (GM-CSF), macrophage inflammatory protein (MIP)-1α, MIP-1β, leukemia inhibitory factor (LIF), and calcium in PIC-induced RAW 264.7 macrophages.
2. Results and Discussion

2.1. Effects of Myristicin on Cell Viability

Besides antibacterial activity [14], it was already reported that myristicin induces glutathione S-transferase and inhibits the tumorigenesis caused by benzo[a]pyrene in the mouse lung [15,16]. Recently, it was reported that liver injury caused by lipopolysaccharides is potently prevented by myristicin treatment [17]. On the contrary, it was suggested that myristicin induces cytotoxicity in human neuroblastoma SK-N-SH cells by an apoptotic mechanism [18]. In this study, myristicin up to a concentration of 50 µM did not decrease the viability of RAW 264.7, while it decreased NO production in RAW 264.7 (Figure 2). Therefore, myristicin concentrations of up to 50 µM were chosen for subsequent experiments.

Figure 2. Effects of myristicin on the cell viability and NO production in RAW 264.7 mouse macrophages. After 24 and 48 h incubation with myristicin, cell viability was evaluated by a modified MTS assay and NO production was measured by the Griess reaction assay in RAW 264.7 cells. Normal group (Normal) was treated with media only. The synthetic analog of dsRNA (PIC, 50 µg/mL of polyinosinic-polycytidylic acid) and lipopolysaccharide (LPS, 1 µg/mL) were used as reference materials. Values are the mean ± SEM of three independent experiments.

2.2. Effects of Myristicin on NO Production

Excess production of NO is implicated in the development of multiple organ failure, with a putative mechanism involving direct mitochondrial inhibition [19]. In this study, myristicin significantly inhibited excessive production of NO in PIC-activated RAW 264.7 (Figure 3A) and THP-1 (Figure 3B). Myristicin also inhibited excessive NO production in RAW 264.7 activated by...
lipopolysaccharide (LPS), a ligand of toll-like receptor 4 (Figure 3C). Since NO is believed to be a major proinflammatory mediator concerned with pathogenic infections by bacteria and viruses, these results suggest that myristicin might have anti-inflammatory activity against the pathologic and excessive production of NO in virus-stimulated macrophages and monocytes.

**Figure 3.** Effects of myristicin on NO production in dsRNA-stimulated RAW 264.7 mouse macrophages and THP-1 human monocytes. NO production was measured after 24 h treatment in RAW 264.7 (A, C) and THP-1 (B) by the Griess reaction assay. Normal group (Nor) was treated with media only. Control group (Con) was treated with the synthetic analog of dsRNA (PIC, 50 µg/mL of polyinosinic-polycytidylic acid) or lipopolysaccharide (LPS, 1 µg/mL) alone. IN denotes indomethacin (0.5 µM). Values are the mean ± SEM of three independent experiments.

\[ * P < 0.05 \text{ vs. Con}; \quad ** P < 0.01; \quad *** P < 0.001. \]

### 2.3. Effects of Myristicin on Cytokine Production

The effects of 24 h treatments with 10, 25, and 50 µM myristicin on cytokine production in PIC-activated RAW 264.7 macrophages are represented in Figure 4. Myristicin significantly decreased the production of IL-6, IL-10, IP-10, MCP-1, MCP-3, GM-CSF, MIP-1α, MIP-1β, and LIF in PIC-induced mouse macrophages in a dose-dependent manner. For comparing anti-inflammatory effect of myristicin with other anti-inflammatory natural materials, chrysin (CH), wogonin (WG), oroxylin A (OR), and emodin (EM) were treated at the concentration of 25 µM, while water extracts of Scutellariae Radix, Lycii Fructus, and Polygoni Radix were treated at 25 µg/mL in these experiments. Although CH, WG, OR, and EM also exerted inhibitory effects on the production of cytokines including IL-6 and GM-CSF in PIC-induced RAW 264.7, myristicin inhibited PIC-induced cytokines production more effectively than other natural materials.

It’s now recognized that resolution of inflammation is an active program controlled by temporal and spatial production of specialized chemical mediators [20]. Like other pathogenic infections, viral infection can induce excessive production of proinflammatory cytokines in immune cells, including macrophages and monocytes, resulting in acute or chronic inflammatory diseases [21].

Increased IL-6 levels often correlate with several inflammatory autoimmune diseases including Crohn’s disease, psoriasis, rheumatoid arthritis, systemic-onset juvenile chronic arthritis, osteoporosis, polyclonal plasmacytosis, malignant plasmacytoma, and encephalomyelitis [20]. In addition it has been demonstrated that IL-6 and soluble form of IL-6 receptor are increased in both serum and intestinal tissues of the patients with active Crohn's disease [22]. LIF, a member of IL-6-family, was also reported to be increased in the colonic mucosa of patients with inflammatory bowel disease and
play a critical role in the susceptibility of colonic host cells to tumor growth in ulcerative colitis patients [23]. IL-10 is a pleiotropic cytokine that modulates the function of adaptive immune-related cells. IL-10, although traditionally considered an anti-inflammatory cytokine, has also been implicated in promoting abnormal angiogenesis in the eye and in the pathobiology of autoimmune diseases such as lupus and encephalomyelitis [24]. In the present study, myristicin inhibited excessive production of IL-6, LIF, and IL-10 in PIC-induced RAW 264.7 macrophages. These results support the contention that myristicin may regulate chronic autoimmune diseases such as Crohn’s disease, psoriasis and encephalomyelitis, which can be provoked with viral infection.

**Figure 4.** Effects of myristicin on cytokine production (IL-6, IL-10, IP-10, MCP-1, MCP-3, GM-CSF, MIP-1α, MIP-1β, LIF, TNF-α, G-CSF, and IL-1α) in dsRNA-stimulated RAW 264.7 mouse macrophages. Fluorescence intensity of each cytokine in the culture medium was measured by a Multiplex bead-based cytokine assay after 24 h incubation. Normal group (N) was treated with media only. Control group (C) was treated with PIC (the synthetic analog of dsRNA, 50 µg/mL of polyinosinic-polyctydylidic acid) alone. As reference materials, chrysin (CH), wogonin (WG), oroxylin A (OR), and emodin (EM) were treated at the concentration of 25 µM, while water extracts of Scutellariae Radix (SR), Lycii Fructus (LF), and Polygoni Radix (PR) were treated at 25 µg/mL. IN denotes indomethacin (0.5 µM). Values are the mean ± SEM of three independent experiments.
Inflammation is a central feature of many lung diseases, including pneumonia, asthma, cystic fibrosis, chronic bronchitis, and emphysema [25]. Adcock and Caramori [25] have reported that asthma, a chronic inflammatory disease of the airway characterized by cellular infiltration and activation, might be induced by overexpression of chemokines and cytokines (such as GM-CSF, MIP-1α, and MIP-1β) released on exposure to inhaled allergens. During lung inflammation, it has been also reported that MCP-1, IP-10, and GM-CSF were increased in the bronchoalveolar lavage fluid [26, 27]. MCP-1 was also reported to be hypersecreted in airway hyperreactivity and chronic airway inflammatory diseases such as asthma [28]. Increased expression of MCP-3 mRNA has been reported in the airway submucosa of patients with asthma [29]. In this study, myristicin displayed significant inhibitory effects on PIC-induced MCP-1, MCP-3, GM-CSF, MIP-1α, and MIP-1β production in RAW 264.7 cells. The current results suggest that myristicin may relieve pulmonary inflammatory diseases such as acute lung injury, bronchial pneumonia, and chronic asthma concerned with viral infection. But myristicin, only at the concentration of 50 µM, significantly inhibited the production of some cytokines such as TNF-α, G-CSF, and IL-1α in PIC-induced RAW 264.7 cells. Thus, myristicin is suggested to be applied in higher concentrations for evaluation of anti-inflammatory effects concerned with TNF-α, G-CSF, and IL-1α.
2.4. Effects of Myristicin on Intracellular Calcium Production

Pathogenic oxidative stress with infection results in macrophage reprogramming with a transient increase of intracellular calcium via the lipid membrane dissociation of the calcium-bound protein annexin VI. This increased cytosolic calcium, in turn, results in the activation of calcium-dependent kinases, leading to enhanced proinflammatory activation [30]. In the start of the inflammation cascade, the endoplasmic reticulum (ER) calcium stores are reduced and intracellular calcium concentration is increased, resulting in ER stress-mediated transcription factor activation and increased inflammatory gene expression [31].

In the present study, myristicin reduced the increase of intracellular calcium level in PIC-activated RAW 264.7 macrophages (Figure 5). Thus, it can be suggested that myristicin down-regulates excessive production of inflammatory mediators in PIC-induced macrophages via the calcium pathway. But whether the intracellular calcium concentration is increased via the calcium-bound membrane protein mobilization or release of calcium from ER could not be confirmed in this study.

Figure 5. Effects of myristicin on calcium production in dsRNA-stimulated RAW 264.7 mouse macrophages. Intracellular production of calcium after 24 h treatment was measured with Fluo-4 calcium assay. Normal group (N) was treated with media only. Control group (Con) was treated with PIC (the synthetic analog of dsRNA, 50 µg/mL of polyinosinic-polycytidylic acid) alone. As reference materials, chrysin (CH), oroxylin A (OR), and emodin (EM) were treated at the concentration of 25 µM. IN denotes indomethacin (0.5 µM). Values are the mean ± SEM of three independent experiments.

3. Experimental

3.1. Reagents

Dulbecco’s Modified Eagle’s Medium (DMEM), RPMI-1640 medium (RPMI), heat-inactivated fetal bovine serum (FBS), penicillin, streptomycin, phosphate-buffered saline (PBS, pH 7.4), and other tissue culture reagents were purchased from Gibco BRL (Grand Island, NY, USA). PIC, griess reagent, and all other chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA). CellTiter 96 Aqueous one solution cell proliferation assay kit was purchased from Promega (Madison, WI, USA). The multiplex bead-based cytokine assay kits used for the determination of cytokine concentration
were purchased from Bio-Rad (Hercules, CA, USA), Panomics (Redwood City, CA, USA), and Millipore (Billerica, MA, USA). The Fluo-4 calcium assay kit was purchased from Molecular Probes (Eugene, OR, USA).

3.2. Cell Culture and Viability

RAW 264.7 mouse macrophages and THP-1 human monocytes were obtained from the Korea Cell Line Bank (Seoul, Korea). RAW 264.7 were cultured in DMEM, as THP-1 in RPMI, supplemented with 10% FBS containing 100 U/mL of penicillin and 100 µg/mL of streptomycin at 37 °C in a 5% CO₂ humidified incubator. Cell viability was assessed by a modified MTS assay using CellTiter 96 Aqueous one solution cell proliferation assay kit (Promega) [32].

3.3. Quantification of NO Production

NO concentration in culture medium was determined by the Griess reaction assay [33]. Specifically, 100 µL of supernatant from each well was mixed with 100 µL of Griess reagent in wells of a 96-well plate. After an incubation of 15 minutes at room temperature, the optical density was determined at 540 nm with a microplate reader (Bio-Rad).

3.4. Multiplex Bead-Based Cytokine Assay

Cytokines released from treated RAW 264.7 macrophages were measured in cell culture supernatants using a Luminex assay based on xMAP technology. This assay was performed with Bio-Plex cytokine assay kits (Bio-Rad), Procarta cytokine assay kits (Panomics), Milliplex kits (Millipore) and Bio-Plex 200 suspension array system (Bio-Rad) as described previously [33,34]. Standard curves for each cytokine were generated using the kit-supplied reference cytokine samples. Production of the following cytokines was assessed: IL-6, IL-10, IP-10, MCP-1, MCP-3, GM-CSF, MIP-1α, MIP-1β, LIF, TNF-α, IL-1α, and G-CSF.

3.5. Intracellular Calcium Assay

After RAW 264.7 cells were seeded in wells of 96-well plates, PIC and myristicin were added to the culture medium, and incubation was carried out for 24 h at 37 °C. Thereafter, the medium was removed and cells were incubated with 100 µL of the Fluo-4 dye loading solution for 30 minutes at 37 °C. After incubation, the fluorescence intensity of each well was determined spectrofluorometrically (Dynex, West Sussex, UK) with excitation and emission filters of 485 nm and 535 nm, respectively.

3.6. Statistical Analysis

The results shown are summarized from three independent experiments and represent the mean ± SEM. Significant differences were examined using a Student’s t-test with SPSS 11.0 software (SPSS, Chicago, IL, USA).
4. Conclusions

Although the precise mechanisms regulating the anti-inflammatory activity of myristicin are not yet known, the current study demonstrates that myristicin has anti-inflammatory properties related with its inhibition of NO, IL-6, IL-10, IP-10, MCP-1, MCP-3, GM-CSF, MIP-1α, MIP-1β, and LIF in PIC-stimulated macrophages via the calcium pathway.

Conflict of Interest

The authors declare no conflict of interest.

Acknowledgements

This research was supported by Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology (2010-0022919).

References and Notes

1. Lee, B.K.; Kim, J.H.; Jung, J.W.; Choi, J.W.; Han, E.S.; Lee, S.H.; Ko, K.H.; Ryu, J.H. Myristicin-induced neurotoxicity in human neuroblastoma SK-N-SH cells. *Toxicol. Lett.* 2005, 157, 49-56.

2. Martins, C.; Doran, C.; Laires, A.; Rueff, J.; Rodrigues, A.S. Genotoxic and apoptotic activities of the food flavourings myristicin and eugenol in AA8 and XRCC1 deficient EM9 cells. *Food Chem. Toxicol.* 2011, 49, 385-392.

3. Hallström, H.; Thuvander, A. Toxicological evaluation of myristicin. *Nat. Toxins* 1997, 5, 186-192.

4. Bakkali, F.; Averbeck, S.; Averbeck, D.; Idaomar, M. Biological effects of essential oils—A review. *Food Chem. Toxicol.* 2008, 46, 446-475.

5. Slamenova, D.; Horvathova, E.; Wsolova, L.; Sramkova, M.; Navarova, J. Investigation of anti-oxidative, cytotoxic, DNA-damaging and DNA-protective effects of plant volatiles eugenol and borneol in human-derived HepG2, Caco-2 and VH10 cell lines. *Mutat. Res.* 2009, 677, 46-52.

6. Narasimhan, B.; Dhake, A.S. Antibacterial principles from Myristica fragrans seeds. *J. Med. Food* 2006, 9, 395-399.

7. Ferret, P.J.; Soum, E.; Negre, O.; Fradelizi, D. Auto-protective redox buffering systems in stimulated macrophages. *BMC Immunol.* 2002, 3, 3.

8. O'Shea, J.J.; Ma, A.; Lipsky, P. Cytokines and autoimmunity. *Nat. Rev. Immunol.* 2002, 2, 37-45.

9. Ware, C.F. Network communications: Lymphotoxins, LIGHT, and TNF. *Annu. Rev. Immunol.* 2005, 23, 787-819.

10. Ulevitch, R.J.; Tobias, P.S. Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. *Annu. Rev. Immunol.* 1995, 13, 437-457.

11. Blair, L.A.; Maggi, L.B., Jr.; Scarim, A.L.; Corbett, J.A. Role of interferon regulatory factor-1 in double-stranded RNA-induced iNOS expression by mouse islets. *J. Biol Chem.* 2002, 277, 359-365.
12. Pereira, R.M.; Teixeira, K.L.; Barreto-de-Souza, V.; Calegari-Silva, T.C.; De-Melo, L.D.; Soares, D.C.; Bou-Habib, D.C.; Silva, A.M.; Saraiva, E.M.; Lopes, U.G. Novel role for the double-stranded RNA-activated protein kinase PKR: Modulation of macrophage infection by the protozoan parasite Leishmania. *FASEB J.* 2010, 24, 617-626.

13. Jiang, W.; Bell, C.W.; Pisetsky, D.S. The relationship between apoptosis and high-mobility group protein 1 release from murine macrophages stimulated with lipopolysaccharide or polyinosinic-polycytidylic acid. *J. Immunol.* 2007, 178, 6495-6503.

14. Narasimhan, B.; Dhake, A.S. Antibacterial principles from *Myristica fragrans* seeds. *J. Med. Food* 2006, 9, 395-399.

15. Ahmad, H.; Tijerina, M.T.; Tobola, A.S. Preferential overexpression of a class MU glutathione S-transferase subunit in mouse liver by myristicin. *Biochem. Biophys. Res. Commun.* 1997, 236, 825-828.

16. Zheng, G.Q.; Kenney, P.M.; Zhang, J.; Lam, L.K. Inhibition of benzo[a]pyrene-induced tumorigenesis by myristicin, a volatile aroma constituent of parsley leaf oil. *Carcinogenesis* 1992, 13, 1921-1923.

17. Morita, T.; Jinno, K.; Kawagishi, H.; Arimoto, Y.; Suganuma, H.; Inakuma, T.; Sugiyama, K. Hepatoprotective effect of myristicin from nutmeg (*Myristica fragrans*) on lipopolysaccharide/dgalactosamine-induced liver injury. *J. Agric. Food Chem.* 2003, 51, 1560-1565.

18. Lee, B.K.; Kim, J.H.; Jung, J.W.; Choi, J.W.; Han, E.S.; Lee, S.H.; Ko, K.H.; Ryu, J.H. Myristicin-induced neurotoxicity in human neuroblastoma SK-N-SH cells. *Toxicol. Lett.* 2005, 157, 49-56.

19. Rao, Y.K.; Fang, S.H.; Tzeng, Y.M. Evaluation of the anti-inflammatory and anti-proliferation tumoral cells activities of *Antrodia camphorata*, *Cordyceps sinensis*, and *Cinnamomum osmophloeum* bark extracts. *J. Ethnopharmacol.* 2007, 114, 78-85.

20. Serhan, C.N.; Chiang, N.; Van, Dyke, T.E. Resolving inflammation: Dual anti-inflammatory and proresolution lipid mediators. *Nat. Rev. Immunol.* 2008, 8, 349-361.

21. Jiang, W.; Bell, C.W.; Pisetsky, D.S. The relationship between apoptosis and high-mobility group protein 1 release from murine macrophages stimulated with lipopolysaccharide or polyinosinic-polycytidylic acid. *J. Immunol.* 2007, 178, 6495-6503.

22. Ito, H. IL-6 and Crohn's disease. *Curr. Drug Targets Inflamm. Allergy* 2003, 2, 125-130.

23. Guimbaud, R.; Abitbol, V.; Bertrand, V.; Quartier, G.; Chauvelot-Moachon, L.; Giroud, J.; Couturier, D.; Chaussade, D.C. Leukemia inhibitory factor involvement in human ulcerative colitis and its potential role in malignant course. *Eur. Cytokine. Netw.* 1998, 9, 607-612.

24. Ishihara, K.; Hirano, T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. *Cytokine. Growth. Factor Rev.* 2002, 13, 357-368.

25. Adcock, I.M.; Caramori, G. Cross-talk between pro-inflammatory transcription factors and glucocorticoids. *Immunol. Cell Biol.* 2001, 79, 376-384.

26. White, K.E.; Ding, Q.; Moore, B.B.; Peters-Golden, M.; Ware, L.B.; Matthay, M.A.; Olman, M.A. Prostaglandin E2 mediates IL-1beta-related fibroblast mitogenic effects in acute lung injury through differential utilization of prostanoid receptors. *J. Immunol.* 2008, 180, 637-646.
27. Srivastava, M.; Jung, S.; Wilhelm, J.; Fink, L.; Bühling, F.; Welte, T.; Bohle, R.M.; Seeger, W.; Lohmeyer, J.; Maus, U.A. The inflammatory versus constitutive trafficking of mononuclear phagocytes into the alveolar space of mice is associated with drastic changes in their gene expression profiles. *J. Immunol.* **2005**, *175*, 1884-1893.

28. Zhang, Y.; Xu, C.B.; Cardell, L.O. Long-term exposure to IL-1beta enhances Toll-IL-1 receptor-mediated inflammatory signaling in murine airway hyperresponsiveness. *Eur. Cytokine. Netw.* **2009**, *20*, 148-156.

29. Barnes, P.J.; Chung, K.F.; Page, C.P. Inflammatory mediators of asthma: An update. *Pharmacol. Rev.* **1998**, *50*, 515-596.

30. Cuschieri, J.; Maier, R.V. Oxidative stress, lipid rafts, and macrophage reprogramming. *Antioxid. Redox. Signal.* **2007**, *9*, 1485-1497.

31. Stout, B.A.; Melendez, K.; Seagrave, J.; Holtzman, M.J.; Wilson, B.; Xiang, J.; Tesfaigzi, Y. STAT1 activation causes translocation of Bax to the endoplasmic reticulum during the resolution of airway mucous cell hyperplasia by IFN-gamma. *J. Immunol.* **2007**, *178*, 8107-8116.

32. Willems, T.; Lefebvre, D.J.; Neyts, J.; De Clercq, K. Diagnostic performance and application of two commercial cell viability assays in foot-and-mouth disease research. *J. Virol. Methods* **2011**, *173*, 108-114.

33. Yoon, S.B.; Lee, Y.J.; Park, S.K.; Kim, H.C.; Bae, H.; Kim, H.M.; Ko, S.G.; Choi, H.Y.; Oh, M.S.; Park, W. Anti-inflammatory effects of Scutellaria baicalensis water extract on LPS-activated RAW 264.7 macrophages. *J. Ethnopharmacol.* **2009**, *125*, 286-290.

34. Yuk, S.S.; Lim, E.M.; Lee, J.Y.; Lee, Y.J.; Kim, Y.S.; Lee, T.H.; Park, S.K.; Bae, H.; Kim, H.M.; Ko, S.G.; Oh, M.S.; Park, W. Antiinflammatory effects of Epimedium brevicornum water extract on lipopolysaccharide-activated RAW264.7 macrophages. *Phytother. R.* **2010**, *24*, 1781-1787.

**Sample Availability:** Samples of the compounds are available from the authors.

© 2011 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).